Charles River Laboratories Q3 FY2026 results
$337.97−0.83%
Charles River Laboratories reported revenue of $983 million, down 2.2% from a year earlier, net income of $333 million and diluted earnings per share of $6.86 against $1.10 for the third quarter of fiscal 2026 (the three months to 26 Sep 2026).
From its quarterly report, filed 4 Nov 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 26 Sep 2026, against the three months to 27 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $982.7M | $1.00B | −2.2% |
| Gross profit | $357.9M | $338.8M | +5.6% |
| Gross margin | 36.4% | 33.7% | +2.7 pts |
| Operating income | $202.6M | $133.8M | +51.4% |
| Operating margin | 20.6% | 13.3% | +7.3 pts |
| Net income | $333.1M | $54.42M | +512% |
| Diluted EPS | $6.86 | $1.10 | +524% |
| Operating cash flow | $254.1M | $213.8M | +18.8% |
| Capital expenditure | $46.81M | $35.58M | +31.6% |
| Free cash flow | $207.3M | $178.2M | +16.3% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Organic revenue (change on a year) | 5.9% | down 0.6 points |
| Remaining performance obligations | $675.3M | up 4.0% |
| Cost of services provided (excluding amortization of intangible assets) revenue | $780.3M | down 3.4% |
| Cost of products sold (excluding amortization of intangible assets) revenue | $202.4M | up 2.8% |
| DSA revenue | $596.3M | down 0.7% |
| RMS revenue | $207.5M | down 2.8% |
| Manufacturing revenue | $178.9M | down 6.2% |
| United States revenue | $541.7M | up 0.8% |
| Europe revenue | $240.1M | down 13.5% |
| Canada revenue | $120.6M | up 3.2% |
| Asia Pacific revenue | $61.6M | up 19.3% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 26 Sep 2026 | $982.7M | −2.2% | $6.86 |
| Q2 FY2026 | 27 Jun 2026 | $1.00B | −2.7% | −$0.03 |
| Q1 FY2026 | 28 Mar 2026 | $995.8M | +1.2% | −$0.30 |
| Q4 FY2025 | 27 Dec 2025 | $994.2M | −0.8% | −$5.62 |
| Q3 FY2025 | 27 Sep 2025 | $1.00B | −0.5% | $1.10 |
| Q2 FY2025 | 28 Jun 2025 | $1.03B | +0.6% | $1.06 |
| Q1 FY2025 | 29 Mar 2025 | $984.2M | −2.7% | $0.50 |
| Q4 FY2024 | 28 Dec 2024 | $1.00B | −1.1% | −$4.20 |
More on Charles River Laboratories: financial statements · revenue · earnings per share
CRL's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
